Mineralys Therapeutics (MLYS) Appoints Jeffrey A. Munsie as Chief Legal Officer

Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 10 Best New Stocks to Invest In According to Hedge Funds.

Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the best new stocks to invest in according to hedge funds. On March 24, Mineralys Therapeutics appointed Jeffrey A. Munsie as Chief Legal Officer to oversee the company’s legal and compliance functions. Munsie brings 25 years of biopharmaceutical experience to the role, having previously served in leadership positions at Orbital Therapeutics, Concert Pharmaceuticals, and Merrimack Pharmaceuticals.

His background spans the full drug development lifecycle, from preclinical stages through commercialization, which the company views as essential for its next phase of growth. In his new role, Munsie will provide strategic counsel as Mineralys Therapeutics Inc. (NASDAQ:MLYS) advances its lead candidate, lorundrostat, which targets hypertension and related conditions like chronic kidney disease and obstructive sleep apnea.

CEO Jon Congleton highlighted Munsie’s proven track record in handling intellectual property strategy, transactions, and compliance as a key asset for the organization. Munsie, a Harvard Law School graduate, expressed his commitment to helping bring the company’s treatments to patients affected by dysregulated aldosterone.

Mineralys Therapeutics (MLYS) Appoints Jeffrey A. Munsie as Chief Legal Officer

Pixabay/Public Domain

Mineralys Therapeutics Inc. (NASDAQ:MLYS) develops therapeutics that target illnesses caused by dysregulated aldosterone. It is working on the development of lorundrostat, an aldosterone synthase inhibitor for cardiorenal conditions. These include chronic kidney disease, hypertension, and obstructive sleep apnea.

While we acknowledge the risk and potential of MLYS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MLYS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.